- Home
- URGN vs GRVY Comparison
URGN vs GRVY Comparison
Compare URGN & GRVY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- GRVY
- Stock Information
- Founded
- URGN 2004
- GRVY 2000
- Country
- URGN United States
- GRVY South Korea
- Employees
- URGN N/A
- GRVY N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- GRVY Business Services
- Sector
- URGN Health Care
- GRVY Consumer Discretionary
- Exchange
- URGN Nasdaq
- GRVY Nasdaq
- Market Cap
- URGN 547.1M
- GRVY 611.8M
- IPO Year
- URGN 2017
- GRVY 2005
- Fundamental
- Price
- URGN $11.19
- GRVY $65.61
- Analyst Decision
- URGN Strong Buy
- GRVY
- Analyst Count
- URGN 5
- GRVY 0
- Target Price
- URGN $44.50
- GRVY N/A
- AVG Volume (30 Days)
- URGN 456.4K
- GRVY 29.1K
- Earning Date
- URGN 11-06-2024
- GRVY 11-12-2024
- Dividend Yield
- URGN N/A
- GRVY N/A
- EPS Growth
- URGN N/A
- GRVY N/A
- EPS
- URGN N/A
- GRVY 9.14
- Revenue
- URGN $89,363,000.00
- GRVY $381,080,758.00
- Revenue This Year
- URGN $14.43
- GRVY N/A
- Revenue Next Year
- URGN $44.44
- GRVY N/A
- P/E Ratio
- URGN N/A
- GRVY $7.18
- Revenue Growth
- URGN 15.64
- GRVY N/A
- 52 Week Low
- URGN $10.60
- GRVY $57.37
- 52 Week High
- URGN $20.70
- GRVY $88.85
- Technical
- Relative Strength Index (RSI)
- URGN 35.94
- GRVY 52.87
- Support Level
- URGN $11.93
- GRVY $64.10
- Resistance Level
- URGN $12.78
- GRVY $69.03
- Average True Range (ATR)
- URGN 0.71
- GRVY 2.43
- MACD
- URGN -0.05
- GRVY 0.11
- Stochastic Oscillator
- URGN 1.36
- GRVY 39.69
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About GRVY GRAVITY Co. Ltd. American Depository Shares
GRAVITY Co Ltd is an online and mobile games developer and publisher based in Korea. Its principal product, Ragnarok Online, is an online game which is available in more than 91 markets. Its games include Ragnarok Online, Requiem, Dragonica (Dragon Saga), Ragnarok Online II, Requiem Online, and R.O.S.E. Online. The company generates revenue from online games, mobile games and other sources including character based merchandise and animation.